Fri 4/3/2020 08:06 ET
DJIA21413.44479.662.24%TELCO160.815.103.17%GOLD1639.802.130.13%Shanghai2771.349.150.33%
S&P 5002526.9057.612.28%BANKS291.898.412.88%OIL27.121.806.64%BITCOIN6996.04206.382.95%
NASDAQ7487.31128.781.72%PHARM553.2017.483.16%US/EU1.080.000.01%Futures2507.389.030.36%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Cellectis SA - CLLS   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CLLS
  
From: trendtn (Rep: 161) reply to trendtnDate: 04/04/2018 10:09
Forum: Cellectis SA - Msg #116Thread #674001209 (Rec: 0)
Re: Clls

French allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis.


Underwriters will have a 30-day over-allotment option to purchase up to 15% of the aggregate offering size. Goldman Sachs & Co. LLC and Citigroup will act as book-runners together with Barclays. Nomura and Oppenheimer & Co. and Ladenburg Thalmann will also participate.

The announcement followed an asset swap of Pfizer's CAR-T therapy development portfolio into the newly founded company Allogene Therapeutics, in which Pfizer will hold a minority stake of 25%. Allogene was formed with Series A financing of US$300m from a consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, as well as others. Under the asset contribution agreement, Allogene receives the global development and commercialisation rights to 16 preclinical CAR-T licenses that Pfizer licensed from Cellectis and Servier, and one clinical asset licensed from Servier, UCART19 in 2014. Pfizer still will have an 8% ownership stake in Cellectis through an equity deal signed in 2014.

Cellectis said it will remain eligible to receive clinical and commercial milestone payments of up to US$2.8bn (US$185m per target for 15 targets) and royalties in the high single digits on net sales of any product that will be commercialised by Allogene under the agreement. Allogene was co-founded and led by former executives of Kite Pharma, whose autologous CAR-T cell assets were acquired by Gilead Sciences, Inc. last year. Allogene's management team will include former Kite CEO Arie Belldegrun, and David Chang, former Executive Vice President R&D and CMO of Kite.

Development of Cellectis’ lead candidate UCART123 was delayed after clinical hold by the FDA following a death due to cytokine release syndrome. In November 2017, the FDA lifted the clinical hold after Cellectis proposed to change dosing. Cellectis' CAR T platform use engineered T-cells from a healthy donor for use in multiple patients. This is distinct from autologous approaches that use a patient's own T-cells to target tumor cells. Since manufacturing of autologous CAR T cell therapies is costly and complex, production of allogenic CAR-T cell therapies is expected to significantly reduce cost thus increasing profits for developers. According to Cellectis, UCARTs (Universal Chimeric Antigen Receptor T-cells) are off-the-shelf products that have the potential to be industrialized and standardised, with consistent pharmaceutical release criteria, over time and from batch to batch.

Share
European BiotechnologyEuropean BiotechnologyEuropean BiotechnologyEuropean BiotechnologyPRINT
YOU MIGHT ALSO LIKE
© ustas/Fotolia.com
Cullinan Oncology partners with MAB Discovery
The companies said they will use MAB Discovery ’s rabbit platform to generate a potent, human immune checkpoint agonist. Last October,...


Santhera licenses CF drug from Polyphor
According to the exclusive global license agreement, Santhera has the right to develop and commercialise Polyphor’s drug candidate in...


Motif Bio to submit NDA for iclaprim
In the US, 3.6 million patients of this population are hospitalised annually. Motif Bio said the antibiotic may be suitable for first-line...

Sign up for our newsletter


E-Mail
Contact Us
Events
Advertise


PRODUCT OF THE WEEK
Equipment, plates and seals from Porvair Sciences for...
Dunn Labortechnik presents a special product range from Porvair Sciences for sample preparation and improved productivity in drug...

SIGN UP FOR OUR FREE NEWSLETTER
SUBSCRIBE TO OUR MAGAZINE
SUBSCRIBE TO OUR MAGAZINE
UP TO DATE
NEWS AND STORIES
PEOPLE
APPOINTMENTS
OPINION
EVENTS
HIGHLIGHTS
THE MAG
ISSUES
SPECIALS
INSIDE
SUBSCRIBE
SERVICE
NEWSLETTER
CONTACT US
IMPRINT
European Biotechnology - first and foremost in European biotech
SIGN UP FOR OUR FREE NEWSLETTER



© BIOCOM AG 2000 - 2018



Reply to trendtn - Msg #2727643 - 04/04/2018 10:08

Clls

Clls offering...looks to be 4-5m shares in the geeks if the Allogene Pfizer deal.
Allogene is for the most part KITE. PFE owbs 25% if the new company.
Offering is annoying but I think will be gathered up institutionally. Why..clls is cheap at 1.35b...kite sold for 10b...and clls also has crispr in addition to cart science...buy the annoying weakness.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser trendtn: Reward | Watch | IgnoreCLLS: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CLLS
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.